Difference between revisions of "Tranexamic acid"

(Text replacement - "Category:Drugs" to "Category:Pharmacology")
(Text replacement - "==Source== <references/>" to "==References== <references/>")
Line 40: Line 40:
 
*[http://www.emdocs.net/txa-use-trauma-update/ EMDocs TXA]
 
*[http://www.emdocs.net/txa-use-trauma-update/ EMDocs TXA]
  
==Source==
+
==References==
 
<references/>
 
<references/>
  
 
[[Category:Pharmacology]]
 
[[Category:Pharmacology]]
 
[[Category:Trauma]]
 
[[Category:Trauma]]

Revision as of 16:44, 25 June 2016

Background

  • Action: Antifibrinolytic agent
  • Competitive inhibitor of plasminogen activation to plasmin
  • Dosing Availability:
    • Ampule of 1 Gm in 10 mL

Indication

Severely bleeding trauma patient, systolic blood pressure of <90 and/or heart rate > 110 beats/min., with expected requirement for massive transfusion.

Contraindication/Exclusion Criteria

  • Greater than 3 hours from injury
  • Known sensitivity to TXA
  • Previous DVT or Pulmonary Embolism

Administration

Adult dose

Total of 2 Grams

  • Initial bolus of 1 Gm over 10 minutes (Slow IV push). Draw up with filter needle.
  • Maintenance: additional 1 Gm over next 8 hours (mix in 50 mL of NS). Call Pharmacy to mix and deliver the continuous infusion.[1]

Pediatric dose

Weight based

  • Initial bolus of 20 mg/kg IV Bolus over 10 minutes
  • Maintenance: 10 mL/kg/hr over next 8 hours

No additional laboratory tests required.

Adverse Reactions

  • Thrombotic events
  • Hypotension with rapid injection
  • Nausea, vomiting, diarrhea
  • Impaired color vision and other visual disturbances

See Also

External Links

References

  1. CRASH-2 collaborators, Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011 Mar 26;377(9771):1096-101,